Final, Group 3, Phase II Trials, page-17

There will be no update from LCT on the current trials as LCT is 'blind' tot he results for some time to come.

Press Release from LCT 22 Dec 2016 highlights:

The next step is for the Data Safety Monitoring Board to consider giving approval to treat the six patients in group 3 with the next dose of NTCELL (120 microcapsules implanted into the putamen on each side of their brain).

The company plans to complete group 3 by the end of February 2017. The company is blind to the results until 26 weeks after completion of group 3 of the trial, at which point the patients who received the placebo will receive the optimal dose of NTCELL.

The Phase IIb trial aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. If the trial is successful, the company will apply for provisional consent to treat paying patients in New Zealand in Q4 2017.

As the company is blind to the results until approx 6 months after this final round is completed, so taking the statement of group 3 being complete by end of next month (Feb) would suggest we will know some time from 1 September 2017.